# Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies

> **NCT02672917** · PHASE1 · TERMINATED · sponsor: **BioNTech Research & Development, Inc.** · enrollment: 118 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** MVT-5873
- **DRUG:** modified FOLFIRINOX (mFOLFIRINOX)
- **DRUG:** gemcitabine + nab-paclitaxel

## Key facts

- **NCT ID:** NCT02672917
- **Lead sponsor:** BioNTech Research & Development, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-01
- **Primary completion:** 2024-08-07
- **Final completion:** 2025-01-14
- **Target enrollment:** 118 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2025-01-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02672917

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02672917, "Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies". Retrieved via MORVS 2026-10-19 from https://api.morvs.ai/clinical/NCT02672917. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*